6-MPG
Latest Information Update: 08 Aug 2002
Price :
$50 *
At a glance
- Originator Tanabe Seiyaku
- Class Antineoplastics
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Dec 1998 New profile
- 30 Dec 1998 Preclinical development for Cancer in Japan (Unknown route)